Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

Bejarano, Victoria; Conaghan, Philip G.; Quinn, Mark; Saleem, Benazir; Emery, Paul

doi:10.1093/rheumatology/keq194

Cited by 45 publications

(37 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients treated with MTX alone, even when achieving remission, will demonstrate progression of damage predicted by subclinical synovitis (103). Long-term data of early remission induction are now available showing long-term benefits (104). For patients with RA, clinical features are insufficient to give an accurate picture of the disease state (105), and joint damage has been shown to progress despite a sustained clinical remission in early rheumatoid arthritis patients after etanercept interruption (106).…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Girolomoni

Griffiths

Krueger

et al. 2014

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact on a patient's life, especially when the disease is moderate to severe. There is evidence that treatment of psoriasis during the first years is conservative and frequently based on topical agents which rarely clear lesions. Treatment with systemic agents including biologics is often undertaken only when topical agents have proved unsuitable, even in patients with moderate to severe disease. However, there is evidence that in other IMIDs (rheumatoid arthritis and Crohn's disease), targeted systemic treatment given early in the treatment pathway may improve long-term patient outcomes. We hypothesize that a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway (''early intervention'') with the goal of complete clearance, may improve control of cutaneous symptoms and may also modify disease course and burden. Critical points to address when designing an early intervention study would include: the definition of psoriasis disease activity; patient selection; intervention selection; and dosing strategies.

show abstract

Section: Rheumatoid Arthritismentioning

confidence: 99%

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Girolomoni

Griffiths

Krueger

et al. 2014

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…A number of reports have described the long-time effectiveness of biologic treatment from two to as long as eight years. Although treatment regimens vary, it has been shown that early and maintained targeted treatment using biologic agents has functional and radiological benefits (68)(69)(70).…”

Section: Biological Agents Targeting Cytokinesmentioning

confidence: 99%

A Paradigm Shift in Rheumatoid Arthritis over the Past Decade

Kaneko

Takeuchi

2014

Intern. Med.

View full text Add to dashboard Cite

Recent advances have improved our understanding of the pathogenesis of rheumatoid arthritis (RA), and the development of new therapeutics, including biological agents, have thus made it possible to strive for remission as a primary goal. Biological agents targeting a specific molecule have powerful functional capabilities, and the introduction of biological therapies has brought about revolutionary progress in RA management, culminating in a paradigm shift. There is clear evidence that a delay in treatment initiation and poor control of disease activity are associated with joint damage progression, so treatment should be started immediately after the diagnosis of RA and adapted according to disease activity as assessed by validated composite measures. In this review, we will summarize the changes in the classification and remission criteria and describe the clinical efficacies of biological agents in RA. We also discuss new promising therapies and propose future perspectives in the rheumatology field.

show abstract

“…Higher rates of remission have been achieved [48], and sustained remission despite withdrawal of TNFi therapy is more readily achievable [49,50]. Evidence supporting the early use of TNFi, before the failure of conventional DMARDs, is increasing such that recent recommendations by the European League Against Rheumatism (EULAR) suggest the use of TNFi therapy in combination with MTX as first-line therapy in patients with poor prognostic signs for rapidly progressive disease, such as early radiographic damage or very high disease activity [51].…”

Section: Future Perspectivementioning

confidence: 99%

Certolizumab pegol in rheumatoid arthritis: a review of Phase III clinical trials and its role in real-life clinical practice

Horton¹,

Das²,

Emery³

2011

International Journal of Clinical Rheumatology

View full text Add to dashboard Cite

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

Abstract: A remission induction regime with an INF-MTX combination for 1 year in early RA can improve long-term clinical outcomes. Larger studies will be required to confirm the implications of these findings.

Cited by 45 publications

References 11 publications

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

A Paradigm Shift in Rheumatoid Arthritis over the Past Decade

Certolizumab pegol in rheumatoid arthritis: a review of Phase III clinical trials and its role in real-life clinical practice

Contact Info

Product

Resources

About